FY2025 EPS Estimate for Puma Biotechnology Lifted by Analyst

Puma Biotechnology, Inc. (NASDAQ:PBYI) – Equities research analysts at Zacks Research upped their FY2025 earnings estimates for shares of Puma Biotechnology in a research note issued on Wednesday, January 22nd. Zacks Research analyst R. Department now expects that the biopharmaceutical company will earn $0.31 per share for the year, up from their prior estimate of $0.28. The consensus estimate for Puma Biotechnology’s current full-year earnings is $0.31 per share. Zacks Research also issued estimates for Puma Biotechnology’s Q4 2026 earnings at ($0.01) EPS and FY2026 earnings at $0.12 EPS.

Puma Biotechnology (NASDAQ:PBYI) last issued its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported $0.41 earnings per share for the quarter, topping analysts’ consensus estimates of $0.31 by $0.10. Puma Biotechnology had a net margin of 9.56% and a return on equity of 41.60%. The business had revenue of $80.50 million during the quarter, compared to analysts’ expectations of $71.32 million. During the same period last year, the company posted $0.12 EPS.

A number of other research firms have also recently commented on PBYI. HC Wainwright reiterated a “buy” rating and set a $7.00 price objective on shares of Puma Biotechnology in a research report on Monday, December 23rd. StockNews.com downgraded shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Friday, December 6th.

Puma Biotechnology Stock Performance

Puma Biotechnology stock opened at $3.03 on Monday. Puma Biotechnology has a fifty-two week low of $2.22 and a fifty-two week high of $7.73. The company has a market capitalization of $148.74 million, a price-to-earnings ratio of 6.31 and a beta of 1.10. The stock has a fifty day moving average of $3.07 and a two-hundred day moving average of $2.98. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 1.42.

Hedge Funds Weigh In On Puma Biotechnology

A number of hedge funds have recently made changes to their positions in the business. Los Angeles Capital Management LLC purchased a new stake in Puma Biotechnology during the 3rd quarter worth $627,000. FMR LLC raised its position in shares of Puma Biotechnology by 27.1% in the 3rd quarter. FMR LLC now owns 118,265 shares of the biopharmaceutical company’s stock valued at $302,000 after purchasing an additional 25,183 shares in the last quarter. Barclays PLC boosted its stake in shares of Puma Biotechnology by 146.5% during the 3rd quarter. Barclays PLC now owns 78,021 shares of the biopharmaceutical company’s stock valued at $199,000 after buying an additional 46,370 shares during the last quarter. Franklin Resources Inc. acquired a new stake in shares of Puma Biotechnology during the third quarter worth approximately $41,000. Finally, State Street Corp increased its stake in shares of Puma Biotechnology by 17.0% in the third quarter. State Street Corp now owns 601,542 shares of the biopharmaceutical company’s stock worth $1,534,000 after buying an additional 87,504 shares during the last quarter. Hedge funds and other institutional investors own 61.29% of the company’s stock.

Insider Activity

In other news, CEO Alan H. Auerbach sold 33,841 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total value of $106,599.15. Following the transaction, the chief executive officer now directly owns 7,029,674 shares in the company, valued at $22,143,473.10. This trade represents a 0.48 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Jeffrey Jerome Ludwig sold 9,437 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total transaction of $29,726.55. Following the sale, the insider now directly owns 108,951 shares of the company’s stock, valued at approximately $343,195.65. This trade represents a 7.97 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 23.70% of the company’s stock.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.